PD-002CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial. (2nd July 2019) - Willenbrock, F; Cox, C; Wilhelm-benartzic, C; Owens, R; Sabbagh, A; Abraham, A; Maughan, T; Hurt, C; O'Neill, E; Mukherjee, S